Bordetella pertussis Filamentous Hemagglutinin (FHA) Antigen BA120VS3

$1,335.00

Summary

Virion/Serion Immunologics Antigen for research use (RUO)
Bordetella pertussis Filamentous Hemagglutinin (FHA) Antigen, recombinant
Suitable for detection of IgA, IgG & IgM antibodies in ELISA
Lot specific concentration, specified in mg/mL
1 mg

SKU: BA120VS3 Category: Infectious disease proteins Tags: antigen, Bordetella pertussis

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Bordetella pertussis Filamentous Hemagglutinin (FHA)
species reactivity	Bordetella pertussis (whooping cough)
applications	ELISA
assay type	Indirect & quantitative
available size	1 mg

Bordetella pertussis Filamentous Hemagglutinin (FHA) Antigen BA120VS3

kit
Research area Infectious Disease
Storage Store at -65°C or lower. Avoid repeated freeze-thaw cycles. Sonicate before use. 10 years from date of manufacture (under recommended storage conditions).
Form liquid
Associated products Bordetella pertussis Filamentous Hemagglutinin (FHA) Antigen (BA120VS3) Bordetella pertussis Toxin Antigen (BA120VS4) Bordetella pertussis whole cell Antigen (BA120VS8) Bordetella pertussis Toxin Human IgA Assay Control (BC1201A) Bordetella pertussis IgA Control Serum (BC120A) Bordetella pertussis IgG Control Serum (BC120G) Bordetella pertussis Toxin IgA ELISA Kit (ESR1201A) Bordetella pertussis Toxin IgG ELISA Kit (ESR1201G) Bordetella pertussis IgA ELISA Kit (ESR120A) Bordetella pertussis IgG ELISA Kit (ESR120G) Bordetella pertussis IgM ELISA Kit (ESR120M)

target relevance
Bordetella pertussis
Description Bacterium that causes whooping cough (pertussis)
Structure Bordetella pertussis is a small, Gram-negative, aerobic coccobacillus belonging to the family Alcaligenaceae. The bacterium is a strictly human pathogen and the primary causative agent of pertussis, commonly known as whooping cough. B. pertussis colonizes the ciliated epithelium of the upper respiratory tract through the action of multiple adhesins, including filamentous hemagglutinin, pertactin, and fimbriae. The organism produces several virulence factors, most notably pertussis toxin, adenylate cyclase toxin, and tracheal cytotoxin, which interfere with host immune responses and contribute to respiratory tract damage. Despite widespread vaccination programs, Bordetella pertussis remains a significant cause of respiratory disease worldwide, particularly among infants and inadequately vaccinated populations.
Diagnosis The diagnosis of Bordetella pertussis infection is performed using microbiological, molecular, and serological methods. Polymerase chain reaction (PCR) testing of nasopharyngeal specimens is the preferred laboratory method during the early stages of infection due to its high sensitivity and rapid turnaround time. Culture of B. pertussis from nasopharyngeal swabs remains the definitive diagnostic method but is less sensitive and requires specialized media and prolonged incubation. Serological assays, including ELISA-based tests that detect antibodies against pertussis toxin and other bacterial antigens, are useful in later stages of disease when bacterial shedding has decreased. Laboratory diagnosis is particularly important because clinical presentation may overlap with other respiratory infections.
Symptoms Bordetella pertussis infection is highly contagious and spreads through respiratory droplets generated during coughing or sneezing. Following an incubation period of approximately seven to ten days, disease typically progresses through three stages. The catarrhal stage resembles a common upper respiratory infection with symptoms including runny nose, mild fever, sneezing, and occasional cough. This is followed by the paroxysmal stage, characterized by severe repetitive coughing fits that may be followed by the characteristic inspiratory 'whoop,' post-tussive vomiting, and exhaustion. In infants, apnea may occur and can be life-threatening. The final convalescent stage involves gradual recovery over weeks to months, although coughing episodes may persist. Complications include pneumonia, seizures, encephalopathy, rib fractures, and, particularly in young infants, death.

Data

FAQ & Publications

Frequently Asked Questions

What is the recommended storage condition for the Bordetella pertussis Filamentous Hemagglutinin (FHA) Antigen BA120VS3?

The Bordetella pertussis Filamentous Hemagglutinin (FHA) Antigen BA120VS3 should be stored at -65°C or lower. It is important to avoid repeated freeze-thaw cycles to maintain antigen integrity. The product has a shelf life of 10 years from the date of manufacture under these recommended storage conditions.

For which antibody types is the Bordetella pertussis FHA Antigen suitable in ELISA applications?

This recombinant Bordetella pertussis Filamentous Hemagglutinin (FHA) Antigen is suitable for the detection of IgA, IgG, and IgM antibodies in ELISA assays. It supports indirect and quantitative assay formats to facilitate antibody detection against Bordetella pertussis FHA.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.